{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:44:58Z","timestamp":1780051498139,"version":"3.53.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Scientific Research Projects Coordination Unit, Istanbul University","award":["33564"],"award-info":[{"award-number":["33564"]}]},{"name":"Scientific Research Projects Coordination Unit, Istanbul University","award":["43303"],"award-info":[{"award-number":["43303"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12026-022-09298-5","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T19:51:02Z","timestamp":1654285862000},"page":"654-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of different cytokines in combination with IL-15 on the expression of activating receptors in NK cells of patients with Beh\u00e7et\u2019s disease"],"prefix":"10.1007","volume":"70","author":[{"given":"Nilgun","family":"Sallakci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhan","family":"Tahrali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut Can","family":"Kucuksezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esin Aktas","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0721-6213","authenticated-orcid":false,"given":"Gunnur","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"issue":"4 Suppl 60","key":"9298_CR1","first-page":"S2","volume":"28","author":"H Behcet","year":"2010","unstructured":"Behcet H, Matteson EL. On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S2-5.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"9298_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/1573397115666190415142426","volume":"16","author":"IG Nieto","year":"2020","unstructured":"Nieto IG, Alabau JLC. Immunopathogenesis of Behcet Disease. Curr Rheumatol Rev. 2020;16(1):12\u201320.","journal-title":"Curr Rheumatol Rev"},{"key":"9298_CR3","unstructured":"Adil A, et al. Behcet disease. Treasure Island (FL): StatPearls Publishing; 2022."},{"issue":"5","key":"9298_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.55563\/clinexprheumatol\/lnvc9k","volume":"38 Suppl 127","author":"G Hatemi","year":"2020","unstructured":"Hatemi G, et al. One year in review 2020: Behcet\u2019s syndrome. Clin Exp Rheumatol. 2020;38 Suppl 127(5):3\u201310.","journal-title":"Clin Exp Rheumatol"},{"key":"9298_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fimmu.2019.00665","volume":"10","author":"B Tong","year":"2019","unstructured":"Tong B, et al. Immunopathogenesis of Behcet\u2019s disease. Front Immunol. 2019;10:665.","journal-title":"Front Immunol"},{"issue":"1","key":"9298_CR6","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/ar4147","volume":"15","author":"G Parlakgul","year":"2013","unstructured":"Parlakgul G, et al. Expression of regulatory receptors on gammadelta T cells and their cytokine production in Behcet\u2019s disease. Arthritis Res Ther. 2013;15(1):R15.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"9298_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","volume":"27","author":"CM Deuter","year":"2008","unstructured":"Deuter CM, et al. Behcet\u2019s disease: ocular effects and treatment. Prog Retin Eye Res. 2008;27(1):111\u201336.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"9298_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/1547691X.2017.1346008","volume":"14","author":"A Salmaninejad","year":"2017","unstructured":"Salmaninejad A, et al. Genetics and immunodysfunction underlying Behcet\u2019s disease and immunomodulant treatment approaches. J Immunotoxicol. 2017;14(1):137\u201351.","journal-title":"J Immunotoxicol"},{"issue":"1","key":"9298_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.humimm.2015.10.001","volume":"77","author":"A Clemente Ximenis","year":"2016","unstructured":"Clemente Ximenis A, et al. In vitro evaluation of gammadelta T cells regulatory function in Behcet\u2019s disease patients and healthy controls. Hum Immunol. 2016;77(1):20\u20138.","journal-title":"Hum Immunol"},{"issue":"10","key":"9298_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.autrev.2011.12.005","volume":"11","author":"ZY Zhou","year":"2012","unstructured":"Zhou ZY, et al. Cytokines and Behcet\u2019s disease. Autoimmun Rev. 2012;11(10):699\u2013704.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"9298_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1365-2133.1985.tb02083.x","volume":"113","author":"F Kaneko","year":"1985","unstructured":"Kaneko F, et al. Natural killer cell numbers and function in peripheral lymphoid cells in Behcet\u2019s disease. Br J Dermatol. 1985;113(3):313\u20138.","journal-title":"Br J Dermatol"},{"key":"9298_CR12","doi-asserted-by":"publisher","first-page":"622306","DOI":"10.3389\/fimmu.2021.622306","volume":"12","author":"UC Kucuksezer","year":"2021","unstructured":"Kucuksezer UC, et al. The role of natural killer cells in autoimmune diseases. Front Immunol. 2021;12:622306.","journal-title":"Front Immunol"},{"key":"9298_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fimmu.2015.00031","volume":"6","author":"NC Horton","year":"2015","unstructured":"Horton NC, Mathew PA. NKp44 and natural cytotoxicity receptors as damage-associated molecular pattern recognition receptors. Front Immunol. 2015;6:31.","journal-title":"Front Immunol"},{"issue":"2","key":"9298_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/icb.2010.78","volume":"89","author":"HJ Pegram","year":"2011","unstructured":"Pegram HJ, et al. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol. 2011;89(2):216\u201324.","journal-title":"Immunol Cell Biol"},{"key":"9298_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3389\/fimmu.2018.00476","volume":"9","author":"A Zingoni","year":"2018","unstructured":"Zingoni A, et al. NKG2D and its ligands: \u201cOne for All, All for One.\u201d Front Immunol. 2018;9:476.","journal-title":"Front Immunol"},{"key":"9298_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fimmu.2013.00069","volume":"4","author":"K Hudspeth","year":"2013","unstructured":"Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol. 2013;4:69.","journal-title":"Front Immunol"},{"key":"9298_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fimmu.2017.00025","volume":"8","author":"NW Zwirner","year":"2017","unstructured":"Zwirner NW, Ziblat A. Regulation of NK cell activation and effector functions by the IL-12 family of cytokines: the case of IL-27. Front Immunol. 2017;8:25.","journal-title":"Front Immunol"},{"issue":"4","key":"9298_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1172\/JCI31860","volume":"117","author":"J Zhang","year":"2007","unstructured":"Zhang J. Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease. J Clin Invest. 2007;117(4):871\u20133.","journal-title":"J Clin Invest"},{"key":"9298_CR19","doi-asserted-by":"crossref","unstructured":"Yasuda K, et al. Interleukin-18 in health and disease. Int J Mol Sci.\u00a02019;20(3).","DOI":"10.3390\/ijms20030649"},{"issue":"8","key":"9298_CR20","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.4049\/jimmunol.162.8.4511","volume":"162","author":"TA Fehniger","year":"1999","unstructured":"Fehniger TA, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol. 1999;162(8):4511\u201320.","journal-title":"J Immunol"},{"key":"9298_CR21","first-page":"205796","volume":"2014","author":"R Romee","year":"2014","unstructured":"Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo). 2014;2014:205796.","journal-title":"Scientifica (Cairo)"},{"key":"9298_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fimmu.2016.00101","volume":"7","author":"CM Nielsen","year":"2016","unstructured":"Nielsen CM, et al. Synergy between common gamma chain family cytokines and IL-18 potentiates innate and adaptive pathways of NK cell activation. Front Immunol. 2016;7:101.","journal-title":"Front Immunol"},{"issue":"1","key":"9298_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/S0100-879X1998000100001","volume":"31","author":"W Carson","year":"1998","unstructured":"Carson W, Caligiuri MA. Interleukin-15 as a potential regulator of the innate immune response. Braz J Med Biol Res. 1998;31(1):1\u20139.","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"9298_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.micinf.2011.10.006","volume":"14","author":"PY Perera","year":"2012","unstructured":"Perera PY, et al. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect. 2012;14(3):247\u201361.","journal-title":"Microbes Infect"},{"issue":"1","key":"9298_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cyto.2008.01.003","volume":"42","author":"C Zhang","year":"2008","unstructured":"Zhang C, et al. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1\/2 phosphorylation. Cytokine. 2008;42(1):128\u201336.","journal-title":"Cytokine"},{"issue":"10","key":"9298_CR26","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/rheumatology\/keh311","volume":"43","author":"M Treusch","year":"2004","unstructured":"Treusch M, et al. Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet\u2019s disease. Rheumatology (Oxford). 2004;43(10):1275\u201382.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"9298_CR27","first-page":"588","volume":"19","author":"Y Suzuki","year":"1992","unstructured":"Suzuki Y, et al. Increased peripheral blood gamma delta+ T cells and natural killer cells in Behcet\u2019s disease. J Rheumatol. 1992;19(4):588\u201392.","journal-title":"J Rheumatol"},{"issue":"2","key":"9298_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/cei.12939","volume":"188","author":"MS Hasan","year":"2017","unstructured":"Hasan MS, et al. Circulating NK cells and their subsets in Behcet\u2019s disease. Clin Exp Immunol. 2017;188(2):311\u201322.","journal-title":"Clin Exp Immunol"},{"key":"9298_CR29","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.3389\/fimmu.2018.02157","volume":"9","author":"M Bonacini","year":"2018","unstructured":"Bonacini M, et al. Higher frequencies of lymphocytes expressing the natural killer group 2D receptor in patients with Behcet disease. Front Immunol. 2018;9:2157.","journal-title":"Front Immunol"},{"issue":"1","key":"9298_CR30","first-page":"126","volume":"71","author":"K Hamzaoui","year":"1988","unstructured":"Hamzaoui K, et al. Natural killer cells in Behcet\u2019s disease. Clin Exp Immunol. 1988;71(1):126\u201331.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"9298_CR31","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/ar3005","volume":"12","author":"Y Yamaguchi","year":"2010","unstructured":"Yamaguchi Y, et al. Natural killer cells control a T-helper 1 response in patients with Behcet\u2019s disease. Arthritis Res Ther. 2010;12(3):R80.","journal-title":"Arthritis Res Ther"},{"issue":"6 Suppl 94","key":"9298_CR32","first-page":"S24","volume":"33","author":"UC Kucuksezer","year":"2015","unstructured":"Kucuksezer UC, et al. Natural killer cells dominate a Th-1 polarized response in Behcet\u2019s disease patients with uveitis. Clin Exp Rheumatol. 2015;33(6 Suppl 94):S24\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"9298_CR33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/08820139.2017.1288240","volume":"46","author":"F Cosan","year":"2017","unstructured":"Cosan F, et al. Natural killer cell subsets and their functional activity in Behcet\u2019s disease. Immunol Invest. 2017;46(4):419\u201332.","journal-title":"Immunol Invest"},{"issue":"6","key":"9298_CR34","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1365-3083.2006.01844.x","volume":"64","author":"K Hamzaoui","year":"2006","unstructured":"Hamzaoui K, et al. Levels of IL-15 in serum and cerebrospinal fluid of patients with Behcet\u2019s disease. Scand J Immunol. 2006;64(6):655\u201360.","journal-title":"Scand J Immunol"},{"issue":"8","key":"9298_CR35","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00296-013-2705-4","volume":"33","author":"JY Choe","year":"2013","unstructured":"Choe JY, et al. The distinct expressions of interleukin-15 and interleukin-15 receptor alpha in Behcet\u2019s disease. Rheumatol Int. 2013;33(8):2109\u201315.","journal-title":"Rheumatol Int"},{"issue":"1","key":"9298_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.imlet.2008.07.009","volume":"121","author":"SJ Curnow","year":"2008","unstructured":"Curnow SJ, et al. Serum cytokine profiles in Behcet\u2019s disease: is there a role for IL-15 in pathogenesis? Immunol Lett. 2008;121(1):7\u201312.","journal-title":"Immunol Lett"},{"key":"9298_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.imlet.2016.12.001","volume":"186","author":"N Gholijani","year":"2017","unstructured":"Gholijani N, et al. An elevated pro-inflammatory cytokines profile in Behcet\u2019s disease: a multiplex analysis. Immunol Lett. 2017;186:46\u201351.","journal-title":"Immunol Lett"},{"issue":"5\u20136","key":"9298_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cyto.2006.08.006","volume":"35","author":"AR French","year":"2006","unstructured":"French AR, et al. IL-18 acts synergistically with IL-15 in stimulating natural killer cell proliferation. Cytokine. 2006;35(5\u20136):229\u201334.","journal-title":"Cytokine"},{"issue":"7","key":"9298_CR39","doi-asserted-by":"publisher","first-page":"e1017701","DOI":"10.1080\/2162402X.2015.1017701","volume":"4","author":"J Cany","year":"2015","unstructured":"Cany J, et al. Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer. Oncoimmunology. 2015;4(7):e1017701.","journal-title":"Oncoimmunology"},{"key":"9298_CR40","doi-asserted-by":"crossref","unstructured":"Criteria for diagnosis of Behcet\u2019s disease. International Study Group for Behcet\u2019s Disease. Lancet. 1990;335(8697):1078\u201380.","DOI":"10.1016\/0140-6736(90)92643-V"},{"issue":"2","key":"9298_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cellimm.2008.08.007","volume":"254","author":"E Aktas","year":"2009","unstructured":"Aktas E, et al. Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 2009;254(2):149\u201354.","journal-title":"Cell Immunol"},{"issue":"6","key":"9298_CR42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","volume":"3","author":"LL Lanier","year":"2015","unstructured":"Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res. 2015;3(6):575\u201382.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"9298_CR43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/ni929","volume":"4","author":"DD Billadeau","year":"2003","unstructured":"Billadeau DD, et al. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol. 2003;4(6):557\u201364.","journal-title":"Nat Immunol"},{"issue":"16","key":"9298_CR44","doi-asserted-by":"publisher","first-page":"9452","DOI":"10.1073\/pnas.1632807100","volume":"100","author":"V Groh","year":"2003","unstructured":"Groh V, et al. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2003;100(16):9452\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"9298_CR45","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1053\/j.gastro.2007.03.025","volume":"132","author":"M Allez","year":"2007","unstructured":"Allez M, et al. CD4+NKG2D+ T cells in Crohn\u2019s disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology. 2007;132(7):2346\u201358.","journal-title":"Gastroenterology"},{"issue":"2","key":"9298_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.imlet.2010.02.005","volume":"129","author":"A Clemente","year":"2010","unstructured":"Clemente A, et al. Phenotype markers and cytokine intracellular production by CD8+ gammadelta T lymphocytes do not support a regulatory T profile in Behcet\u2019s disease patients and healthy controls. Immunol Lett. 2010;129(2):57\u201363.","journal-title":"Immunol Lett"},{"issue":"1","key":"9298_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2337\/db06-0493","volume":"56","author":"M Rodacki","year":"2007","unstructured":"Rodacki M, et al. Altered natural killer cells in type 1 diabetic patients. Diabetes. 2007;56(1):177\u201385.","journal-title":"Diabetes"},{"key":"9298_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.imlet.2019.10.006","volume":"216","author":"I Tahrali","year":"2019","unstructured":"Tahrali I, et al. CD3(-)CD56(+) NK cells display an inflammatory profile in RR-MS patients. Immunol Lett. 2019;216:63\u20139.","journal-title":"Immunol Lett"},{"issue":"2","key":"9298_CR49","doi-asserted-by":"publisher","first-page":"e31959","DOI":"10.1371\/journal.pone.0031959","volume":"7","author":"N Nielsen","year":"2012","unstructured":"Nielsen N, et al. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94\/NKG2A. PLoS ONE. 2012;7(2):e31959.","journal-title":"PLoS ONE"},{"issue":"3","key":"9298_CR50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1084\/jem.20011149","volume":"195","author":"G Ferlazzo","year":"2002","unstructured":"Ferlazzo G, et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002;195(3):343\u201351.","journal-title":"J Exp Med"},{"issue":"10","key":"9298_CR51","doi-asserted-by":"publisher","first-page":"e0186223","DOI":"10.1371\/journal.pone.0186223","volume":"12","author":"SJ Lin","year":"2017","unstructured":"Lin SJ, et al. Activating and inhibitory receptors on natural killer cells in patients with systemic lupus erythematosis-regulation with interleukin-15. PLoS ONE. 2017;12(10):e0186223.","journal-title":"PLoS ONE"},{"issue":"4","key":"9298_CR52","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.4049\/jimmunol.1102002","volume":"188","author":"FB Thoren","year":"2012","unstructured":"Thoren FB, et al. Human NK cells induce neutrophil apoptosis via an NKp46-and Fas-dependent mechanism. J Immunol. 2012;188(4):1668\u201374.","journal-title":"J Immunol"},{"issue":"13","key":"9298_CR53","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1016\/j.celrep.2018.03.023","volume":"22","author":"S Sheppard","year":"2018","unstructured":"Sheppard S, et al. The murine natural cytotoxic receptor NKp46\/NCR1 controls TRAIL protein expression in NK Cells and ILC1s. Cell Rep. 2018;22(13):3385\u201392.","journal-title":"Cell Rep"},{"issue":"2","key":"9298_CR54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00417-007-0659-5","volume":"246","author":"K Fujimori","year":"2008","unstructured":"Fujimori K, et al. Circulating neutrophils in Behcet disease is resistant for apoptotic cell death in the remission phase of uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246(2):285\u201390.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"9298_CR55","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1084\/jem.168.5.1621","volume":"168","author":"M Cebrian","year":"1988","unstructured":"Cebrian M, et al. Triggering of T-cell proliferation through aim, an activation inducer molecule expressed on activated human-lymphocytes. J Exp Med. 1988;168(5):1621\u201337.","journal-title":"J Exp Med"},{"issue":"6","key":"9298_CR56","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1172\/JCI200319112","volume":"112","author":"D Sancho","year":"2003","unstructured":"Sancho D, et al. CD69 downregulates autoimmune reactivity through active transforn ing growth factor-beta production in collagen-induced arthritis. J Clin Investig. 2003;112(6):872\u201382.","journal-title":"J Clin Investig"},{"issue":"10","key":"9298_CR57","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.molmed.2013.07.006","volume":"19","author":"R Gonzalez-Amaro","year":"2013","unstructured":"Gonzalez-Amaro R, et al. Is CD69 an effective brake to control inflammatory diseases? Trends Mol Med. 2013;19(10):625\u201332.","journal-title":"Trends Mol Med"},{"issue":"1","key":"9298_CR58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4049\/jimmunol.182.1.111","volume":"182","author":"YM Han","year":"2009","unstructured":"Han YM, et al. CD69(+)CD4(+)CD25(-) T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol. 2009;182(1):111\u201320.","journal-title":"J Immunol"},{"issue":"3","key":"9298_CR59","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12020-015-0662-2","volume":"51","author":"A Rodriguez-Munoz","year":"2016","unstructured":"Rodriguez-Munoz A, et al. Levels of regulatory T cells CD69(+)NKG2D(+)IL-10(+) are increased in patients with autoimmune thyroid disorders. Endocrine. 2016;51(3):478\u201389.","journal-title":"Endocrine"},{"key":"9298_CR60","doi-asserted-by":"publisher","first-page":"2513829","DOI":"10.1155\/2017\/2513829","volume":"2017","author":"M Vitales-Noyola","year":"2017","unstructured":"Vitales-Noyola M, et al. Patients with systemic lupus erythematosus show increased levels and defective function of CD69(+) T regulatory cells. Mediators Inflamm. 2017;2017:2513829.","journal-title":"Mediators Inflamm"},{"issue":"7","key":"9298_CR61","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jop.12514","volume":"46","author":"M Vitales-Noyola","year":"2017","unstructured":"Vitales-Noyola M, et al. Quantitative and functional analysis of CD69(+) T regulatory lymphocytes in patients with periodontal disease. J Oral Pathol Med. 2017;46(7):549\u201357.","journal-title":"J Oral Pathol Med"},{"key":"9298_CR62","first-page":"S120","volume":"115","author":"V Rus","year":"2005","unstructured":"Rus V, et al. Increased expression and production of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) by T cells from lupus patients is a feature of active disease. Clin Immunol. 2005;115:S120\u2013S120.","journal-title":"Clin Immunol"},{"key":"9298_CR63","doi-asserted-by":"crossref","unstructured":"Onder M, B.M., G\u00fcrer MA, G\u00fclekon A, Sezgin P, Imir T, Natural cellular cytotoxicity in Beh\u00e7et\u2019s disease. J Dermatol. 1994;4(Apr;21):239\u201343.","DOI":"10.1111\/j.1346-8138.1994.tb01729.x"},{"issue":"1\u20132","key":"9298_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","volume":"294","author":"G Alter","year":"2004","unstructured":"Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294(1\u20132):15\u201322.","journal-title":"J Immunol Methods"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-022-09298-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T06:55:57Z","timestamp":1675752957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-022-09298-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["9298"],"URL":"https:\/\/doi.org\/10.1007\/s12026-022-09298-5","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"19 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}